Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M

Guardant Health, Inc.

2025-Q2 EPS reported -$1.57 revenue$435,559,000

Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).
Non-GAAP gross margin 66% (vs 60% YoY); net loss $99.9M ($0.80) vs $102.6M ($0.84) YoY.
2025 revenue guidance raised to $915-925M (24-25% growth) from prior $880-890M; non-GAAP gross margin guidance 63-64%.
Shield screening test volume expected 68,000-73,000; Screening revenue guidance raised to $55-60M.
Free cash flow burn -$65.9M in Q2 vs -$99.1M; core business ex-Screening on track for FCF breakeven in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.